SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SCLN
4.47
0.00 (0.00%)
Real-time:   10:10AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.41 - 4.49
52 week 4.24 - 6.30
Open 4.45
Vol / Avg. 24,715.00/259,363.00
Mkt cap 232.25M
P/E 22.58
Div/yield     -
EPS 0.20
Shares 51.96M
Beta 2.43
Inst. own 55%
Apr 8, 2014
SciClone Pharmaceuticals, Inc. at Needham Healthcare Conference
Mar 12, 2014
Q4 2013 SciClone Pharmaceuticals, Inc. Earnings Release
Mar 12, 2014
	 Q4 2013 SciClone Pharmaceuticals, Inc. Earnings Conference Call - Webcast
Feb 11, 2014
SciClone Pharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 0.11% 8.63%
Operating margin 2.49% 8.21%
EBITD margin - 9.81%
Return on average assets 0.08% 6.19%
Return on average equity 0.10% 7.57%
Employees 870 -
CDP Score - -

Address

Suite 900, 950 Tower Lane
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company�s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone�s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc.

Officers and directors

Jon S. Saxe Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Wilson W. Cheung CPA Chief Financial Officer, Senior Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 49
Bio & Compensation  - Reuters
Lan Xie Vice President - Finance, Chief Financial Officer - China Operations
Age: 40
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Bio & Compensation  - Reuters
Min Yin Vice President - Internal Audit
Age: 42
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Director
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Bio & Compensation  - Reuters
Gregg Anthony Lapointe CPA Independent Director
Age: 54
Bio & Compensation  - Reuters